Establishment Labs Holdings Inc. (ESTA) Q3 2024 Earnings Call Transcript Summary
Establishment Labs Holdings Inc. (ESTA) Q3 2024 Earnings Call Transcript Summary
Net loss from operations improved to $13.1 million from $21 million in the same period last year.The following is a summary of the Establishment Labs Holdings Inc. (ESTA) Q3 2024 Earnings Call Transcript:
以下是Establishment Labs Holdings Inc.（ESTA）2024年第三季度業績會議呼叫記錄摘要：
Financial Performance:
財務表現：
Q3 revenue reached $40.2 million, a 4.5% increase year-over-year.
Gross profit for Q3 was $25.7 million or 63.9% of revenue, impacted by revaluation of euro-denominated inventory.
Net loss from operations improved to $13.1 million from $21 million in the same period last year.
Adjusted EBITDA was a loss of $7 million, improving from a loss of $16.3 million in the previous year.
第三季度營業收入達到4020萬美元，同比增長4.5%。
第三季度毛利潤爲2570萬美元，佔營業收入的63.9%，受歐元庫存重新計價影響。
運營淨虧損從去年同期的2100萬美元降至1310萬美元。
調整後的EBITDA爲虧損700萬美元，較去年同期的虧損1630萬美元有所改善。
Business Progress:
業務進展：
FDA approval of Motiva Implants marked a significant milestone, with a strong U.S. market entry exceeding expectations.
Decommissioning of the B15 manufacturing facility to consolidate production and optimize costs.
Expansion in China facilitated by strategic partnerships and targeted capital infusion, enhancing the Motiva and Mia Femtech product lines.
Strategic efforts to drive growth in U.S. with increased salesforce and operational investments.
Continuous enhancement and global rollout of Mia Femtech, showing promising data and market reception.
Motiva植入物獲得FDA批准標誌着一個重要里程碑，美國市場表現強勁，超出預期。
關閉B15製造設施，以整合生產並優化成本。
通過戰略合作伙伴關係和有針對性的資本注入在中國市場擴張，增強Motiva和Mia Femtech產品線。
通過增加賽富時和運營投資來推動美國市場增長的戰略努力。
持續改進和全球推廣Mia Femtech，展示出有前景的數據和市場接受度。
Opportunities:
機會：
Strong initial U.S. market response to Motiva Implants underscores significant growth potential in this high-margin market.
Expansion in the Chinese market through strategic financing, building capacity for long-term growth.
New minimally invasive Mia Femtech category expanding globally, attracting new customer segments at premium pricing.
Motiva植入物在美國市場的強勁初期反應凸顯出這一高毛利市場的巨大增長潛力。
通過戰略融資在中國市場拓展，爲長期增長建立能力。
新型微創Mia Femtech類別全球擴張，以高溢價定價吸引新的客戶群。
Risks:
風險：
Continued soft macroeconomic conditions in Latin America, particularly in Brazil, potentially hindering regional performance.
Initial supply challenges following the decommissioning of a manufacturing unit impacting the ability to meet short-term demand.
拉丁美洲持續不利的宏觀經濟條件，特別是在巴西，可能會影響區域業績。
一家制造業-半導體單元停產後初期供應挑戰，影響了滿足短期需求的能力。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。